Synthetic biology funds back companies programming biology to create new materials, medicines, and chemicals. From engineered microbes to cell-free systems, these investors fuel the transition from petrochemical to biological manufacturing.
Showing 60 of 88 funds
San Francisco, United States
Menlo Park, United States
Chicago, United States
Isle of Man, United Kingdom
Brooklyn, United States
Berlin, Germany
Chicago, United States
Cambridge, United States
São Paulo, Brazil
United States
Berkeley, United States
New York, United States
Copenhagen, Denmark
Zurich, Switzerland
San Francisco, United States
San Francisco, United States
Paris, France
San Francisco, United States
London, United Kingdom
San Francisco, United States
United States
London, United Kingdom
London, United Kingdom
Berlin, Germany
San Francisco, United States
Cambridge, United States
San Francisco, United States
Los Altos, United States
Bangkok, Thailand
Tokyo, Japan
Berlin, Germany
Buenos Aires, Argentina
London, United Kingdom
Riyadh, Saudi Arabia
San Diego, United States
Brussels, Belgium
Barcelona, Spain
United States
United States
New York, United States
St. Louis, United States
Rio de Janeiro, Brazil
Shanghai, China
Bethesda, United States
San Francisco, United States
Berlin, Germany
Boston, United States
Auckland, New Zealand
United States
United States
Boston, United States
Helsinki, Finland
United States
Berlin, Germany
London, United Kingdom
New York, United States
London, United Kingdom
Palo Alto, United States
San Diego, United States
San Francisco, United States